Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ: KYMR )

34.70 +1.25 (+3.75%)
Streaming Delayed Price Updated: 3:22 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Demystifying Kymera Therapeutics: Insights From 6 Analyst Reviews
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
The Latest Analyst Ratings For Kymera Therapeutics
Via Benzinga
Preview: Kymera Therapeutics's Earnings
Via Benzinga
Insights Ahead: Kymera Therapeutics's Quarterly Earnings
Via Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
The Analyst Landscape: 7 Takes On Kymera Therapeutics
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
Via Benzinga
Unveiling 6 Analyst Insights On Kymera Therapeutics
Via Benzinga
Why Kymera Therapeutics Stock Is Soaring Today
Kymera's lead pipeline candidate received some good news. 
Via The Motley Fool
This BJ's Wholesale Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Via Benzinga
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... 
Via Benzinga
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
Via Benzinga
Demystifying Kymera Therapeutics: Insights From 5 Analyst Reviews
Via Benzinga
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
KYMR Stock Earnings: Kymera Therapeutics Beats EPS, Misses Revenue for Q1 2024
KYMR stock results show that Kymera Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Piper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To Know
Via Benzinga
Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views
Via Benzinga
Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering
Shares soared and then tumbled Friday after the company offered $275 million in public shares. 
Via Investor's Business Daily
More Than $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed slightly higher on Monday, there were a few notable insider trades. 
Via Benzinga
Preview: Kymera Therapeutics's Earnings
Via Benzinga
The Latest Analyst Ratings for Kymera Therapeutics
Via Benzinga
Earnings Scheduled For February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. 
Via Benzinga
Deep Dive Into Kymera Therapeutics Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Analyst Expectations for Kymera Therapeutics's Future
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Kymera Therapeutics: Here's What You Need To Know
Via Benzinga
Why CalAmp Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
Why Shares of Kymera Therapeutics Jumped on Tuesday
The company had a big bounce after hitting a 52-week low the day before. 
Via The Motley Fool
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.